News

Orasis Pharmaceuticals announces approval of Qlosi, a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials.

Orasis Pharmaceuticals CEO Elad Kedar and COO Paul Smith sat down with David Hutton to discuss the FDA approval of Qlosi, a preservative-free low-dose eyedrops for presbyopia.

EVO ICLs, which evolved from early generation ICLs, offer a lens-based alternative for the correction/reduction of refractive error in people who currently use glasses and/or contact lenses for vision correction.

Mutations in the EMC1 gene appear to be associated with FEVR, a severe ocular condition.

According to a human study of older adults, grape intake improved macular pigment accumulation and downregulated harmful biomarkers.

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.

According to the United States Attorney’s Office Southern District of Texas, Michael Hochman, MD, is set to be arraigned Oct. 12 before U.S. Magistrate Judge Christopher dos Santos.

AffaMed Technologies is the joint venture between AffaMed Therapeutics and SIFI.

The Phase 3 DIAMOND trial of OCS-01 in Diabetic Macular Edema (DME) presents encouraging results, meeting primary and secondary endpoints.

Polish researchers found positive bacterial cultures in premature infants correlated with severe retinopathy of prematurity (ROP), suggesting a potential prognostic marker for early ROP development.

The ANTERION from Heidelberg Engineering offers a range of advanced diagnostic tools, including IOL power calculation, corneal topography, and tomography.

Prevent Blindness emphasizes the importance of proper eye protection, as exposure to the sun during an eclipse can cause "eclipse blindness" or retinal burns, which can be temporary or permanent.

Researchers at the Warsaw, Poland-based International Center for Translational Eye Research decided to change that by introducing a new imaging method derived from optical coherence tomography. This led to the creation of even more advanced spatio-temporal optical coherence tomography.

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.

Stephanie Marioneaux, MD, an ophthalmologist and cornea specialist, addresses the widespread issue of digital eye strain in honor of World Sight Day.

A groundbreaking study conducted by the International Agency for the Prevention of Blindness (IAPB) and Kevin Frick, PhD, from Johns Hopkins University reveals that prioritizing better eye health could inject a staggering $50.4 billion annually into the US economy.

Held the second Thursday each October, World Sight Day is an annual day of awareness to focus global attention on blindness and vision impairment.

NVK002 is currently under FDA review, with a PDUFA date scheduled for January 31, 2024.

World Sight Day on October 12 highlights the vital role of eye care in workplaces. The International Agency for the Prevention of Blindness urges employers to prioritize eye health, aiming to enhance well-being, safety, and productivity.

According to Roche, faricimab (Vabysmo)showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.

Academy’s 2023 program taking place in San Francisco.

The team focused on the research pf the senescent phenotypes of human corneal and conjunctival epithelial cells.

The authors of a case series say silicone oil droplets from silicone used to lubricate the McKesson syringes is the most likely cause of the droplets presumed to cause the floaters.

According to the company, study enrollment is planned to commence during Q1 2024 following IND allowance by the FDA.

According to the company, a change from base line best corrected visual acuity based on an average at week 44, 48 and 52 serves as the primary endpoint.

Physicians explore how other specialties adopted and integrated remote monitoring into plans.

G6501 is a suspension of human allogeneic retinal pigmented epithelial (RPE) cells currently in development for the treatment of GA secondary to age-related macular degeneration (AMD).

The company announced preliminary US net revenues of about $74 million for the injection, approved by the FDA earlier this year.

The Person of Vision Award gala will be held on March 14, 2024.